Nvidia: Earnings Fail To Impress Again
Nvidia Corporation beats earnings estimates, but the stock remains flat. Most growth has been priced in. Find out why NVDA ...
Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight
Candel Therapeutics' CAN-2409 shows a 14.5% improvement in prostate cancer survival. Discover why CADL stock stays a "Buy" ...